Back to NewsPublished: 21 Jan 2026Download AppJoin TelegramWhy JBCP's 16% EBITDA Surge Could Signal a 22% EPS Boom – What Investors Must Know#JBCP#Pharma#EBITDA#EPS#Investment#Indian Stocks#Healthcare#Financial AnalysisDownload AppJoin CommunityShare Article